lorlatinib
Pfizer Reports 27 Percent Oncology Growth in Q4, Touts Progress in ADC and Breast Cancer Trials
Premium
The firm recorded Q4 oncology revenues of $4.06 billion compared to $3.19 billion in the same period in 2023.
Pfizer's Lorbrena Produces Longest Progression-Free Survival Seen in ALK-Positive NSCLC Patients
At five years, 60 percent of patients receiving first-line Lorbrena were alive without progression, according to Phase III data reported at ASCO.
With Seagen integrated into its business, Pfizer has new sources of revenue and forthcoming data readouts on precision oncology drugs.
Pfizer Reports Mixed Revenues for Oncology Products in Q4, Looks to Advancing Pipeline in 2024
Premium
With the completion of its acquisition of Seagen in December, the firm is aiming to become a leader in precision oncology.
Pfizer Oncology Revenues Fall 6 Percent as Firm Anticipates Seagen Acquisition
Several of Pfizer's precision oncology products including Ibrance, Xalkori, and Braftovi saw declines in Q3.